Wealth Enhancement Advisory Services LLC cut its position in ARK Genomic Revolution ETF (BATS:ARKG – Free Report) by 11.6% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 39,268 shares of the company’s stock after selling 5,156 shares during the period. Wealth Enhancement Advisory Services LLC’s holdings in ARK Genomic Revolution ETF were worth $1,005,000 at the end of the most recent reporting period.
Several other large investors also recently made changes to their positions in the company. First Horizon Advisors Inc. grew its stake in shares of ARK Genomic Revolution ETF by 9.4% in the 2nd quarter. First Horizon Advisors Inc. now owns 4,650 shares of the company’s stock valued at $109,000 after buying an additional 398 shares during the period. Prospect Financial Services LLC boosted its stake in ARK Genomic Revolution ETF by 3.7% during the 2nd quarter. Prospect Financial Services LLC now owns 14,093 shares of the company’s stock valued at $331,000 after purchasing an additional 500 shares during the last quarter. Bridges Investment Management Inc. boosted its stake in ARK Genomic Revolution ETF by 3.8% during the 2nd quarter. Bridges Investment Management Inc. now owns 14,121 shares of the company’s stock valued at $332,000 after purchasing an additional 517 shares during the last quarter. Brown Miller Wealth Management LLC boosted its stake in ARK Genomic Revolution ETF by 5.5% during the 3rd quarter. Brown Miller Wealth Management LLC now owns 17,974 shares of the company’s stock valued at $460,000 after purchasing an additional 933 shares during the last quarter. Finally, Dynamic Advisor Solutions LLC boosted its stake in ARK Genomic Revolution ETF by 7.8% during the 3rd quarter. Dynamic Advisor Solutions LLC now owns 13,590 shares of the company’s stock valued at $348,000 after purchasing an additional 989 shares during the last quarter.
ARK Genomic Revolution ETF Price Performance
ARKG stock opened at $24.78 on Wednesday. The company’s 50-day moving average is $24.98 and its 200-day moving average is $25.07.
About ARK Genomic Revolution ETF
The ARK Genomic Revolution ETF (ARKG) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund is an actively managed fund that targets companies involved in the genomics industry. ARKG was launched on Oct 31, 2014 and is managed by ARK.
Featured Stories
- Five stocks we like better than ARK Genomic Revolution ETF
- ETF Screener: Uses and Step-by-Step Guide
- Palantir Cracks $50, Is There Still Time to Get on Board?
- How to Calculate Stock Profit
- Insider Buying Signals Upside for These 3 Stocks
- 5 discounted opportunities for dividend growth investors
- These 2 Big Players Are Set to Compete With Elon Musk’s Starlink
Want to see what other hedge funds are holding ARKG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ARK Genomic Revolution ETF (BATS:ARKG – Free Report).
Receive News & Ratings for ARK Genomic Revolution ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ARK Genomic Revolution ETF and related companies with MarketBeat.com's FREE daily email newsletter.